• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Deferiprone and idiosyncrasic neutropenia: light and shadow.去铁酮与特发性中性粒细胞减少症：光明与阴影
Blood Adv. 2024 Nov 12;8(21):5651-5652. doi: 10.1182/bloodadvances.2024013479.
2
Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count.轻度中性粒细胞减少症患者继续使用去铁酮治疗可能不会导致中性粒细胞计数出现更严重的下降。
Eur J Haematol. 2014 Apr;92(4):337-40. doi: 10.1111/ejh.12241. Epub 2014 Jan 30.
3
Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.在临床实践中，偏离地拉罗司治疗的安全指南可能与粒细胞缺乏症风险的增加无关。
Pediatr Blood Cancer. 2014 May;61(5):879-84. doi: 10.1002/pbc.24920. Epub 2013 Dec 30.
4
Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy.接受去铁酮单一疗法的土耳其和叙利亚儿童地中海贫血患者中性粒细胞减少症的发生率。
Pediatr Hematol Oncol. 2016 Feb;33(1):51-8. doi: 10.3109/08880018.2015.1106627. Epub 2016 Feb 26.
5
Safety profile of the oral iron chelator deferiprone: a multicentre study.口服铁螯合剂去铁酮的安全性概况：一项多中心研究。
Br J Haematol. 2000 Feb;108(2):305-12. doi: 10.1046/j.1365-2141.2000.01866.x.
6
Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data.地拉罗司治疗患者的严重中性粒细胞减少症和感染风险率：28 年的数据。
Blood Adv. 2024 Nov 12;8(21):5641-5649. doi: 10.1182/bloodadvances.2023012316.
7
Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.口服铁螯合剂去铁酮在中国依赖输血的地中海贫血儿童中的安全性概况
Curr Drug Saf. 2016;11(2):137-44. doi: 10.2174/1574886310666150930113957.
8
A multi-center safety trial of the oral iron chelator deferiprone.口服铁螯合剂去铁酮的多中心安全性试验。
Ann N Y Acad Sci. 1998 Jun 30;850:223-6. doi: 10.1111/j.1749-6632.1998.tb10478.x.
9
Deferiprone-induced agranulocytosis: 20 years of clinical observations.去铁酮诱导的粒细胞缺乏症：20年临床观察
Am J Hematol. 2016 Oct;91(10):1026-31. doi: 10.1002/ajh.24479. Epub 2016 Aug 4.
10
Deferiprone-Induced Agranulocytosis : A Critical Review of Five Rechallenged Cases.去铁酮诱导的粒细胞缺乏症：5例再次激发病例的批判性综述。
Clin Drug Investig. 1997 Jun;13(6):345-9. doi: 10.2165/00044011-199713060-00007.

本文引用的文献

1
Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.在一个大型输血依赖型β-地中海贫血患者队列中，铁螯合剂对铁负荷和长期发病率及死亡率结局的影响存在差异，这些患者在 10 多年的时间里一直接受同一种单一疗法治疗。
Blood Cells Mol Dis. 2024 Jul;107:102859. doi: 10.1016/j.bcmd.2024.102859. Epub 2024 May 29.
2
Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement.先天性纯红细胞再生障碍性贫血综合征的诊断、治疗及监测：国际共识声明
Lancet Haematol. 2024 May;11(5):e368-e382. doi: 10.1016/S2352-3026(24)00063-2.
3
Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data.地拉罗司治疗患者的严重中性粒细胞减少症和感染风险率：28 年的数据。
Blood Adv. 2024 Nov 12;8(21):5641-5649. doi: 10.1182/bloodadvances.2023012316.
4
The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action.《欧洲成人及儿童中性粒细胞减少症诊断与管理指南：欧洲血液学协会与EuNet-INNOCHRON成本行动之间的共识》
Hemasphere. 2023 Mar 30;7(4):e872. doi: 10.1097/HS9.0000000000000872. eCollection 2023 Apr.
5
Agranulocytosis in patients with Diamond-Blackfan anaemia (DBA) treated with deferiprone for post-transfusion iron overload: A retrospective study of the French DBA cohort.接受去铁酮治疗输血后铁过载的钻石黑范贫血（DBA）患者的粒细胞缺乏症：法国DBA队列的回顾性研究
Br J Haematol. 2022 Oct;199(2):285-288. doi: 10.1111/bjh.18366. Epub 2022 Jul 19.
6
Idiosyncratic Drug-Induced Neutropenia and Agranulocytosis in Elderly Patients.老年患者的特异质性药物诱导的中性粒细胞减少症和粒细胞缺乏症
J Clin Med. 2020 Jun 10;9(6):1808. doi: 10.3390/jcm9061808.
7
State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies.特异质性药物诱导的中性粒细胞减少症或粒细胞缺乏症的研究现状，重点关注生物疗法。
J Clin Med. 2019 Sep 1;8(9):1351. doi: 10.3390/jcm8091351.
8
The Role of Deferiprone in Iron Chelation.去铁酮在铁螯合中的作用。
N Engl J Med. 2018 Nov 29;379(22):2140-2150. doi: 10.1056/NEJMra1800219.
9
Non-chemotherapy drug-induced neutropenia: key points to manage the challenges.非化疗药物引起的中性粒细胞减少症：应对挑战的关键要点。
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):187-193. doi: 10.1182/asheducation-2017.1.187.
10
Nonchemotherapy drug-induced agranulocytosis in children detected by a prospective pharmacovigilance program.通过一项前瞻性药物警戒计划检测到的儿童非化疗药物所致粒细胞缺乏症
Pediatr Hematol Oncol. 2016 Oct-Nov;33(7-8):441-456. doi: 10.1080/08880018.2016.1234523. Epub 2016 Dec 6.

Deferiprone and idiosyncrasic neutropenia: light and shadow.

作者信息

Fioredda Francesca, Forni Gian Luca

机构信息

Unit of Hematology, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

出版信息

Blood Adv. 2024 Nov 12;8(21):5651-5652. doi: 10.1182/bloodadvances.2024013479.

DOI:10.1182/bloodadvances.2024013479
PMID:39476036
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11564060/
Abstract
摘要